Soligenix (NASDAQ:SNGX) Issues Earnings Results

Soligenix (NASDAQ:SNGXGet Free Report) announced its quarterly earnings data on Friday. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.02, reports. The firm had revenue of $0.10 million during the quarter, compared to analysts’ expectations of $0.20 million. Soligenix had a negative return on equity of 157.88% and a negative net margin of 1,025.66%.

Soligenix Trading Down 1.7 %

SNGX stock opened at $0.40 on Monday. Soligenix has a 52 week low of $0.37 and a 52 week high of $2.00. The business has a 50-day simple moving average of $0.53 and a 200 day simple moving average of $0.60. The company has a quick ratio of 1.52, a current ratio of 1.55 and a debt-to-equity ratio of 0.40.

Soligenix Company Profile

(Get Free Report)

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Beh├žet's Disease.

See Also

Earnings History for Soligenix (NASDAQ:SNGX)

Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with's FREE daily email newsletter.